Akari Therapeutics (AKTX) Income towards Parent Company (2014 - 2026)

Akari Therapeutics (AKTX) has reported Income towards Parent Company for 13 consecutive years, with -$14.5 million the latest figure, recorded in Q1 2026.

• Quarterly Income towards Parent Company fell 290.15% year-over-year to -$14.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$29.4 million (down 64.84% YoY) and the FY2025 annual result came in at -$17.3 million, up 12.6% from the prior year.
• Income towards Parent Company fell to -$14.5 million in Q1 2026 per AKTX's latest filing, from -$5.3 million in the prior quarter.
• Over the last five years, Income towards Parent Company for AKTX reached as high as -$2.5 million in Q3 2023 and fell as low as -$47.3 million in Q4 2023.
• A 5-year average of -$8.4 million and a median of -$4.9 million in 2023 frame the typical range for Income towards Parent Company.
• Annual changes were most pronounced in 2024 — Income towards Parent Company soared 92.03% — and 2026, when it plunged 290.15%.
• Year by year, Income towards Parent Company stood at -$5.8 million in 2022, then slumped by 714.24% to -$47.3 million in 2023, then surged by 92.03% to -$3.8 million in 2024, then tumbled by 40.46% to -$5.3 million in 2025, then plunged by 172.84% to -$14.5 million in 2026.
• According to Business Quant data, Income towards Parent Company over the past three periods registered -$14.5 million, -$5.3 million, and -$6.4 million for Q1 2026, Q4 2025, and Q3 2025 respectively.